Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer

Davendra P.S. Sohal, James M. Metz, Weijing Sun, Bruce J. Giantonio, John P. Plastaras, Gregory Ginsberg, Michael L. Kochman, Ursina R. Teitelbaum, Kathleen Harlacker, Daniel F. Heitjan, Michael D. Feldman, Jeffrey A. Drebin, Peter J. O'Dwyer

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Purpose: Platinum compounds or bevacizumab, in combination with gemcitabine, achieved good response rates in early studies in advanced pancreatic cancer. This prompted an evaluation of an aggressive approach to allow better local control and resectability in locally advanced disease. Methods: We piloted a combination of gemcitabine/oxaliplatin/bevacizumab Q2w for four cycles, followed by oxaliplatin and bevacizumab added to infusional 5-FU and radiotherapy, in patients with locally advanced pancreatic cancer. Results: Nineteen patients were treated, of whom 17 completed the protocol-specified treatment. Median age was 60 years. Fifteen had unresectable, and four had borderline resectable disease. Toxicity of chemotherapy was moderate: grade III neutropenia (5) and grade I/II nausea, vomiting, fatigue, and neuropathy. During chemoradiation, major grade III toxicities were nausea and vomiting (3 each). One patient had intractable pain early on, necessitating treatment cessation. Response rate for 18 evaluable patients was 11 % (by RECIST); five patients (4 inoperable, 1 borderline, 26 %) went on to have surgery. One-year overall survival was 58 % and progression-free survival was 37 %. Conclusions: This combination, associated with higher response rates in metastatic disease, had a lower than expected response rate in primary tumors. Although tolerable, our approach failed to affect clinical outcomes meaningfully.

Original languageEnglish (US)
Pages (from-to)1485-1491
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume71
Issue number6
DOIs
StatePublished - Jun 1 2013

Keywords

  • Bevacizumab
  • Chemoradiation
  • Locally advanced
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Sohal, D. P. S., Metz, J. M., Sun, W., Giantonio, B. J., Plastaras, J. P., Ginsberg, G., Kochman, M. L., Teitelbaum, U. R., Harlacker, K., Heitjan, D. F., Feldman, M. D., Drebin, J. A., & O'Dwyer, P. J. (2013). Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 71(6), 1485-1491. https://doi.org/10.1007/s00280-013-2147-4